Uncategorized

Una investigación reciente revela que un traumatismo craneoencefálico puede modificar la respuesta posterior del cerebro al estrés.   El estudio es obra de un equipo internacional liderado por investigadores del Departamento de Biología Celular, Genética y F …

En el sarcoma de Ewing, una proteína anómala formada por la fusión de dos genes puede activar regiones repetitivas del ADN que normalmente permanecen silenciadas y convertirlas en elementos reguladores de genes. Este mecanismo contribuye de forma importante al desarrollo del tum …

Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first TROP2-directed ADC to do so in this setting, Merck told BioSpace.

As a Jan. 1 deadline looms for payers to adopt new prior authorization tech, Epic’s Vice President of Value-Based Care Ryan Bohochik breaks down the industry’s progress so far.

Cuts to federal programs and the loss of enhanced subsidies on the exchanges could deepen an existing healthcare affordability crisis, according to a new report from the Commonwealth Fund.

At AdvaMed’s The MedTech Conference, CEOs from top medical device companies shared how they navigate difficult times, inflation and new technologies.

When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintenance setting—a potentially “practice-changing” outcome, according to Truist Securities.

After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last week spurred a stock selloff for both partners.

While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same period was muted, with most of the yearly gains for the U.S. biotech-specific index largely driven by the first half of 2026.

JNJ-6143, which came from Johnson & Johnson’s $3 billion takeover of Halda Therapeutics in 2025, showed a 75% overall response rate in the Phase 1 readout.